Premium
A noncontrolled trial of anti‐ TNF ‐ α chimeric monoclonal antibody (infliximab, R emicade ® ) in exudative age‐related macular degeneration
Author(s) -
Hagen P. Martin,
Baarsma G. Seerp,
Bilsen Christel E.,
Kuijpers Robert W.,
Laar Jan A.,
Ent Marianne,
Daele Paul L.,
Veeger Nico J.,
Vingerling Johannes R.,
Missotten Tom O.
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.12471
Subject(s) - medicine , macular degeneration , infliximab , choroidal neovascularization , ophthalmology , bevacizumab , certolizumab pegol , ranibizumab , uveitis , surgery , tumor necrosis factor alpha , chemotherapy